I realize that. In Quebec, there are more drugs that are covered by drug plans. I wonder where the problem lies. Is it because of the way you work? Health Canada can decide to approve a drug, but the opposite can happen when there is an assessment of the effectiveness of a drug compared to its cost. The opposite sometimes happens. Quebec does not have to go through those types of steps, and more drugs and products are approved.
Does the problem lie with Health Canada or with your organization? There appears to be some confusion. I'm trying to understand how the effectiveness of the Common Drug Review process compares to the amount of money being dedicated to improving its procedures.